| For: | Pollard CM, Suster MS, Cora N, Carbone AM, Lymperopoulos A. GRK5 is an essential co-repressor of the cardiac mineralocorticoid receptor and is selectively induced by finerenone. World J Cardiol 2022; 14(4): 220-230 [PMID: 35582468 DOI: 10.4330/wjc.v14.i4.220] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8462/full/v14/i4/220.htm |
| Number | Citing Articles |
| 1 |
Aurora Ferro, Andrea Segreti, Simone Pasquale Crispino, Riccardo Cricco, Anna Di Cristo, Martina Ciancio, Fiorella Gurrieri, Gian Paolo Ussia, Francesco Grigioni. Exploring the Role of Genetic and Genomic Factors in Therapeutic Response to Heart Failure: A Comprehensive Analytical Review. Genes 2025; 16(7) doi: 10.3390/genes16070801
|
| 2 |
Lucas Salgado Rezende de Mendonça, Sergio Senar, Luana Lorena Moreira, José Antônio Silva Júnior, Moni Nader, Luciana Aparecida Campos, Ovidiu Constantin Baltatu. Evidence for the druggability of aldosterone targets in heart failure: A bioinformatics and data science-driven decision-making approach. Computers in Biology and Medicine 2024; 171 doi: 10.1016/j.compbiomed.2024.108124
|
| 3 |
Heng Zhang, Meng Yao Li, Wei Deng. Finerenone: a next-generation nonsteroidal mineralocorticoid receptor antagonist reshaping the management of cardiovascular and metabolic diseases. Biochemical Pharmacology 2026; 252 doi: 10.1016/j.bcp.2026.118201
|
| 4 |
Yafei Huang, Wenyu Zou, Xindi Jiang, Jing Cheng, Jia Zheng. Mitochondrial Homeostasis in Diabetic Cardiomyopathy: From Dysfunction to Therapeutic Strategies. Antioxidants 2026; 15(3) doi: 10.3390/antiox15030399
|
| 5 |
Jing Wang, Haojie Xue, Jinyu He, Li Deng, Julong Tian, Yang Jiang, Jian Feng. Therapeutic potential of finerenone for diabetic cardiomyopathy: focus on the mechanisms. Diabetology & Metabolic Syndrome 2024; 16(1) doi: 10.1186/s13098-024-01466-x
|